“Breast cancer was the furthest thing from my mind,” Jacob Johnson tells PEOPLE ...

Fred Hutch Cancer Center hematologists took center stage at the 2026 Tandem Meetings, a multidisciplinary meeting of experts ...

Melatonin and zinc oxide nanoparticles may protect male reproductive health during chemotherapy, study suggests. A recent study in Reproductive and Developmental Medicine shows that combining ...

March 12, 2026 7:30am EDT Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ("SOC") ...

In Hugo’s case, a shipment of the treatment he needed had been held back by the Peruvian medicine regulator because the drugs ...

Pathological complete response at surgery was higher with INT230-6 pre-treatment plus Keynote-522 (5/7; 71.4%) than with Keynote-522 alone (2/6; 33%), with one evaluation pending. Grade ≥3 adverse ...

The evolving story of GLP-1 receptor agonists in oncology has yet another new chapter.Several studies presented at San Antonio Breast Cancer Symposium suggested the medications may help extend ...

The following is an English translation of an article originally published in Spanish in Salud con Lupa. Para leer este artículo en español, haga clic aquí. Peru's Ministry of Health ...

Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ...

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Heron Therapeutics (HRTX-Q) from The Globe and Mail including charting and trades.